Neutropenia and thrombocytopenia induced by quetiapine monotherapy: a case report and review of literature Antipsychotic drugs can cause neutropenia which can progress to life-threatening agranulocytosis.
INTRODUCTION
Antipsychotic drugs, most notably clozapine, have a risk of causing neutropenia. Other antipsychotic drugs are less known to be associated with neutropenia 1, 2 . Since monitoring of white blood cell (WBC) counts during treatment with other antipsychotics is not recommended, delayed diagnosis and severe complications may be o b s e r v e d 1 . Q u e t i a p i n e f u m a r a t e i s a dibenzodiazepine derivative with a chemical structure similar to clozapine and olanzapine. It has affinity for histamine, alpha-2 adrenergic autoreceptors, serotonin 5HT-2, and dopamine receptors 3 . Neutropenia (neutrophil count <1.5x10 9 /L) and thrombocytopenia (platelet count<150x10 9 /L) are very rare side-effects of quetiapine [4] [5] [6] [7] . Hematological toxicity of quetiapine is more common when concomitant medication is involved 8 . In the current paper, a case of neutropenia and thrombocytopenia induced by quetiapine monotherapy is described along with relevant review of the literature.
CASE REPORT
A 69-year-old male patient with a previous diagnosis of bipolar I disorder (BD-I) was referred with symptoms of decreased sleep, logorrhea and increased energy levels over the last two weeks. He had not been on medication for the previous 2 years. He had a history of poor drug compliance. He reported olanzapine induced weight gain, risperidone and aripiprazole related extrapyramidal side effects and emesis associated with lithium therapy. The patient was hospitalized with a diagnosis of BD-I manic episode and due to low incidence of side effects he was started on quetiapine at 600 mg/day. He did not have a history of systemic diseases and his body mass index was within normal limits. On initial admission all hematological parameters were within normal ranges.
On the 20 th day of treatment the patient's body temperature was 39ºC. Blood, urine and throat cultures, complete blood count, biochemistry including creatine phosphokinase and hepatitis panel were examined. Erythyrocyte sedimentation rate (ESR) was 42 (normal range 0-20) and the C-reactive protein value was 10.3 mg/dl (normal range <0.5), while other laboratory values were normal. There was no rigidity on neurological examination. Bilateral rales were detected on physical examination. With a preliminary diagnosis of pneumonia the patient was started on prophylactic intravenous 1 g ceftriaxone twice daily. No significant elevation was observed in respiratory system viral markers, and there was no growth in cultures. Fever persisted during ceftriaxone therapy. Four days later, leukocyte count decreased to 2.7x10 9 /L (normal range: 4.8-10.8x10 9 /L) and platelet count to 77x10 9 /L (normal range: 130-400x10 9 /L). Respiration rate was 40/min and oxygen saturation decreased to 84%. On consultation to infectious diseases department, the patient was suspected of having a viral pneumonia caused by a probable H1N1 virus which might have caused leukopenia and thrombocytopenia and specific blood tests were ordered to rule it out. Quetiapine therapy was discontinued and the patient was transferred to the intensive care department. On the 3 rd day of monitoring in intensive care, blood cell counts returned to normal ranges. The patient was transferred to the psychiatry department and started on quetiapine at 200 mg/day, gradually increasing to 600 mg/day. The blood test for H1N1 virus was reported to be negative. Seven days after initiation of quetiapine therapy for the second time, leukocyte count was 1.1x10 9 /L, neutrophil count 0.3x10 9 /L and platelet count 111x10 9 /L, while other laboratory findings were normal. At peripheral blood smear, neutrophil value was 21%, monocyte 14%, lymphocyte 65%, and reticulocyte 2%. Despite receiving filgrastim (G-CSF analogue) therapy for 5 days, leukocyte count decreased to 0.9x10 9 /L and neutrophil count to 0.13x10 9 /L. No monocytes, basophils or eosinophils were determined. Bone marrow biopsy revealed druginduced myeloid suppression which was likely to be caused by quetiapine. Quetiapine therapy was discontinued and two days later, leukocyte count increased to 6.2x10 9 /L, neutrophil count to 3.3x10 9 /L and platelet count to 109x10 9 /L. A final diagnosis of quetiapine-induced leuhopenia and thrombocytopenia was made and filgrastim therapy was discontinued and lithium 600 mg/day was initiated. Fourteen days after discontinuation of quetiapine, platelet count was measured to be 184x10 9 /L. Lithium therapy was maintained at a dose of 1200 mg/day. All blood counts were normal at patient's discharge.
DISCUSSION
The literature search from 1998 to August 2015 through PubMed database using the keywords q u e t i a p i n e , l e u k o p e n i a , n e u t r o p e n i a , granulocytopenia and thrombocytopenia revealed 21 case reports (Table 1) . This report describes a case of neutropenia and thrombocytopenia induced by quetiapine monotherapy in a patient with a diagnosis of BD-I manic episode. Hematological abnormalities were resolved after discontinuation of quetiapine therapy. To the best of our knowledge, this is the first report of neutropenia and thrombocytopenia induced by quetiapine monotherapy from Turkey and the second such report in the literature.
The review of the literature revealed three cases o f q u e t i a p i n e -r e l a t e d n e u t r o p e n i a a n d thrombocytopenia 1, 9, 10 . Quetiapine was used in combination with valproate in two cases while in the other 9,10 , similar to our case, hematological side-effects developed with quetiapine monotherapy1. Hematological side-effects resolved in all cases when quetiapine was discontinued. In t h e r e p o r t e d c a s e s , n e u t r o p e n i a a n d thrombocytopenia occurred in the 2 nd week, 5 th week and 4 th year of treatment at a daily quetiapine dose range of 400-600 mg. In our case, adverse effects developed in the 3 rd week of treatment with 600 mg of quetiapine. There has been only one case report describing quetiapine-associated pancytopenia 11 . Additionally, thrombocytopenia alone was reported in a case receiving a quetiapine and valproic acid combination 12 .
The cause of quetiapine-induced neutropenia and thrombocytopenia is unclear. Studies investigating antipsychotic-related leukopenia have been performed with clozapine. Since the pharmacological profile and chemical structure of quetiapine are similar to those of clozapine, it has been suggested that quetiapine may lead to neutropenia and thrombocytopenia through direct toxicity or immune-mediated destruction 6, [12] [13] [14] [15] . The electrophilic nitrenium ion generated by the oxidation of clozapine is thought to bind to neutrophils 12 . It has been suggested that the bound nitrenium ions either lead to direct cell death or cause neutrophil apoptosis due to oxidative stress 16, 17 . According to another theory, however, the formation of neutrophil antibodies with the binding of nitrenium ions to neutrophil proteins leads to neutrophil destruction through immunemediated toxicity. The above mentioned theories for neutropenia are also proposed to apply for thrombocytopenia. However, it is unclear whether these mechanisms hypothesized for clozapinerelated neutropenia would also apply to quetiapine. Dose dependence has also been proposed in quetiapine-related neutropenia 18 . Advanced age and low body weight are factors that lead to higher plasma quetiapine concentrations. Valproate has been observed to increase plasma quetiapine levels by 77% due to its inhibitory effect on cytochrome p450 19 . This observation explains why neutropenia is more common in elderly patients receiving a combination of quetiapine and valproate. The majority of cases reported in the literature were using quetiapine and valproate combination therapy 4, 5, 9, 10, [20] [21] [22] . Our case is distinct in that neutropenia, leukopenia, and thrombocytopenia were induced by quetiapine monotherapy at a standard therapeutic dose of 600 mg. The patient had normal weight, however, his advanced age may also be a factor contributing to a higher plasma quetiapine concentration due to fact that reduced renal clearance with aging.
Monitoring blood counts is recommended during clozapine therapy since the occurrence of adverse effects of neutropenia associated with clozapine is well-known. Our report underlines the importance of checking blood counts during administration of quetiapine, although there are no guidelines on this issue. We think that clinicians should be aware of this rare but hazardous sideeffect.
